Table 2 Virological and immunological treatment responses at 12 months among Yerelon cohort patients who initiated antiretroviral
Viral Load | Total | P-value | ||
|---|---|---|---|---|
< 1000 copies /mL n (%) | ≥ 1000 copies /mL n (%) | |||
CD4 + T cell increase | ||||
< 100 cells | 25 (23.81) | 12 (66.67) | 37 | |
≥ 100 cells | 80 (76.19) | 6 (33.33) | 86 | 0.0003 |
Total | 105 | 18 | 123 | |
Baseline age: median (IQR) | 33.02 (30.01–39.02) | 30.8 (27.69–40.15) | 0.5694 | |
Baseline CD4 + T cell count: median (IQR) | 139 (74–200) | 158 (130–214 | 0.2144 | |
HIV-1 Viral load (log 10copies/mL): median (IQR) | 5.26 (4.85–5.58 | 4.80 (4.02–4.85 | 0.0687 | |